(CDAX, Technology)



Pun/	(11.1.1)	Value Indicators:	EUR	Share data:		Description:	
Buy	(Hold)	DCF:	51.94	Bloomberg:	DAM GR	Producer and Distributor of	
-UD 52 00				Reuters:	DAMG	for special applications in t	ne
EUR 52.00	(EUR 54.00)			ISIN:	DE0005498901	industry.	
		Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2020e
Dia		Market cap:	131.9	Freefloat	30.8 %	Beta:	1.5
Price	EUR 37.40	No. of shares (m):	3.5	Arrow Electronics	69.2 %	Price / Book:	1.2 x
Upside	39.0 %	EV:	99.0			Equity Ratio:	70 %
		Freefloat MC:	40.6				
		Ø Trad. Vol. (30d):	31.89 th				

Affected early, overcome early

Figures Q1/2	2020:							Comment on Figures:
Figures in EUR m	Q1/20	Q1/20e	Q1/19	уоу	2020e	2019	уоу	 Data Modul AG was one of the first companies to be badly affected
Sales	45.5	67.0	63.5	-28.4%	185.0	203.3	-9.0%	 the corona crisis. This initially affected supply chains, but subsequer also important customers.
EBIT margin	3.2 7.0%	5.9 8.8%	5.1 8.0%	-37.3%	11.1 6.0%	10.2 5.0%	8.9%	 However, the reported earnings for the first quarter show that the company is maintaining a relatively stable course through this crisis. Although there are signs of a further decline in sales and earnings in second quarter, the overall developments can be classified as rathe uncritical.

In 2019, the company was already strongly affected by the economic and political environment, e.g. China-US trade tensions, Brexit, the crisis in German mechanical engineering, and the changes in the automotive industry. At this point, the company reacted to the new market environment with significant capacity and structural adjustments (including significant relocations of production facilities to Poland).


In the first quarter, the company was one of the first companies in the supply chain to be affected by the developing corona crisis. The company responded early to supply-chain uncertainties with intelligent supply planning. The drastic falls in demand in certain areas (e.g. catering and gaming) that followed in the first quarter and probably also in the second quarter are not hitting the company unprepared. Some of these falls can even be made up by growth in other areas (e.g. Data Modul provides the monitors for ventilators medical customers). Within the various production lines, it can respond relatively flexibly to fluctuations in demand. With the figures presented, the company has already impressively shown that it can cope very well with even a sharp decline in sales. The company is also well positioned with regards to the balance sheet (equity ratio almost 70%, cash and cash equivalents of EUR 26m as of December 31). In particular, however, the main negative news flow should now be anticipated and priced in.

With a price target of EUR 52 (54), the share is now rated as Buy (Hold) again.

	Changes in E FY End: 31.12. in EUR m Sales EBIT EPS	Estimates: 2020e (old) 219.5 16.9 3.36	+ / - -15.7 % -34.3 % -37.8 %	2021e (old) 230.4 18.0 3.57	+ / - -6.7 % -21.1 % -24.4 %	2022e (old) n.a. n.a. n.a.	+ / - n.m. n.m. n.m.	 Comment on Changes: The EBIT of the first quarter (EUR 3.2m) should be significantly again in the second quarter. In contrast, a significant recover become apparent from the third quarter onwards. Historic levels of sales and profitability should be reached again With the announced planned dividend payment of 50% of the announced planned divi
--	--	---	--	---	---------------------------------------	--	-------------------------------	--

80 - 75 -	FY End: 31.12. in EUR m	CAGR (19-22e)	2016	2017	2018	2019	2020e	2021e	2022e
70 Marcharthan Marcharthan	Sales	3.6 %	197.1	218.3	241.4	203.3	185.0	215.0	225.9
65 -	Change Sales yoy		9.3 %	10.7 %	10.6 %	-15.8 %	-9.0 %	16.2 %	5.1 %
60 -	Gross profit margin		23.2 %	21.8 %	22.3 %	21.6 %	22.0 %	22.0 %	22.0 %
55 - Minune Minune M	EBITDA	17.6 %	17.1	18.3	23.4	15.6	17.0	21.9	25.4
50 - Vin y when y	Margin		8.7 %	8.4 %	9.7 %	7.7 %	9.2 %	10.2 %	11.3 %
45 - 40 -	EBIT	20.0 %	15.0	15.9	20.8	10.2	11.1	14.2	17.6
40 35 -	Margin		7.6 %	7.3 %	8.6 %	5.0 %	6.0 %	6.6 %	7.8 %
30 - W	Net income	22.4 %	10.2	10.6	14.3	6.5	7.4	9.5	11.9
07/19 09/19 11/19 01/20 03/20 05/20	EPS	22.2 %	2.90	3.01	4.05	1.85	2.09	2.70	3.38
Data Modul CDAX (normalised)	EPS adj.	22.2 %	2.90	3.01	4.05	1.85	2.09	2.70	3.38
Data Modal OD/St (Normalised)	DPS	102.7 %	0.12	0.12	0.12	0.12	1.00	1.00	1.00
Rel. Performance vs CDAX:	Dividend Yield		0.3 %	0.2 %	0.2 %	0.2 %	2.7 %	2.7 %	2.7 %
1 month: 2.9 %	FCFPS		0.65	0.64	1.45	0.99	3.60	1.50	3.45
	FCF / Market cap		1.5 %	0.9 %	2.1 %	1.6 %	9.6 %	4.0 %	9.2 %
6 months: -7.2 %	EV / Sales		0.7 x	1.1 x	0.9 x	1.0 x	0.5 x	0.5 x	0.4 x
Year to date: -7.8 %	EV / EBITDA		8.3 x	13.2 x	9.6 x	12.5 x	5.8 x	4.4 x	3.5 x
Trailing 12 months: -33.6 %	EV / EBIT		9.5 x	15.2 x	10.7 x	19.2 x	8.9 x	6.9 x	5.0 x
ç	P/E		15.1 x	24.1 x	17.0 x	33.1 x	17.9 x	13.9 x	11.1 x
Company events:	P / E adj.		15.1 x	24.1 x	17.0 x	33.1 x	17.9 x	13.9 x	11.1 x
	FCF Potential Yield		5.8 %	3.7 %	5.1 %	1.4 %	10.2 %	12.4 %	14.4 %
	Net Debt		-12.6	-14.4	-19.2	-20.7	-32.9	-34.7	-43.3
	ROCE (NOPAT)		19.1 %	17.4 %	20.5 %	9.0 %	10.1 %	12.9 %	15.6 %
	Guidance:	n.a.							






Company Background

- Display solutions for OEMs. With its own products, Data Modul forms the value-added connection between panel producers (LG, Sharp, Samsung etc.) and customers. Trade products complete the offering.
- Displays segment: distribution of standard and added-value products (e.g. additional equipping of the displays with PC components and software).
- In the Systems segment, Data Modul mainly develops and sells its own products and customer-specific solutions. This includes e.g. special monitors for marine navigation or medical technology.
- Increasingly important areas of business growth are embedded computer solutions and touch solutions.

Competitive Quality

- Europe's largest display distributor.
- Focus on niche markets that are too small to be directly served by large display manufacturers, which leads to comparatively low competitive intensity.
- Strong customer loyalty with in-house design (Design-In) of customers' products.
- Earlier access to new technologies through the Distribution business.
- Expertise built up over 40 years.





DCF model														
	Detaile	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	
Sales	185.0	215.0	225.9	237.2	249.1	261.5	274.6	288.3	302.7	317.9	333.8	350.5	361.0	
Sales change	-9.0 %	16.2 %	5.1 %	5.0 %	5.0 %	5.0 %	5.0 %	5.0 %	5.0 %	5.0 %	5.0 %	5.0 %	3.0 %	2.0 %
EBIT	11.1	14.2	17.6	19.0	19.9	20.9	22.0	23.1	24.2	25.4	26.7	28.0	28.9	
EBIT-margin	6.0 %	6.6 %	7.8 %	8.0 %	8.0 %	8.0 %	8.0 %	8.0 %	8.0 %	8.0 %	8.0 %	8.0 %	8.0 %	
Tax rate (EBT)	30.0 %	30.0 %	30.0 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	
NOPAT	7.8	9.9	12.3	13.0	13.6	14.3	15.0	15.8	16.6	17.4	18.3	19.2	19.8	
Depreciation	5.9	7.7	7.8	9.5	10.0	10.5	11.0	11.5	12.1	12.7	13.4	14.0	14.4	
in % of Sales	3.2 %	3.6 %	3.5 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	
Changes in provisions	0.0	0.0	0.0	-0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	
Change in Liquidity from														
- Working Capital	-2.9	6.4	0.1	2.6	0.8	0.7	3.4	3.6	3.7	3.9	4.1	4.3	2.7	
- Capex	4.0	6.0	8.0	9.5	10.0	10.5	11.0	11.5	12.1	12.7	13.4	14.0	14.4	
Capex in % of Sales	2.2 %	2.8 %	3.5 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	4.0 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	12.6	5.2	12.1	10.0	12.9	13.6	11.7	12.3	12.9	13.6	14.2	14.9	17.1	18
PV of FCF	11.9	4.5	9.5	7.2	8.4	8.1	6.3	6.1	5.8	5.6	5.3	5.1	5.3	73
share of PVs		15.95 %						38.89	9 %					45.16 %
Model parameter							Valuat	ion (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20	032e	8	39			
								al Value		7	73			
Debt ratio	0.00 %		Financial S	•		1.50		al liabilitie			4			
Cost of debt (after tax)	1.7 %		Liquidity (s	hare)		1.50		n liabilities	;		2			
Market return	7.00 %		Cyclicality			1.50	Hybrid	•			0			
Risk free rate	1.50 %		Transpare Others	ncy		1.50 1.50		y interest val. of inv	ootmonto		0 0			
			Uners			1.00	Liquidit		connents			No. of sha	ares (m)	3.5
WACC	9.75 %		Beta			1.50	Equity	,		18		Value per	()	
													(,
Sensitivity Value per Sh	aro (ELID)												
sensitivity value per SI		,												

		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.68	10.8 %	44.98	45.39	45.82	46.28	46.76	47.28	47.82	1.68	10.8 %	37.50	40.42	43.35	46.28	49.21	52.13	55.06
1.59	10.3 %	47.39	47.87	48.39	48.93	49.51	50.12	50.78	1.59	10.3 %	39.58	42.70	45.81	48.93	52.04	55.16	58.28
1.55	10.0 %	48.71	49.23	49.79	50.38	51.02	51.69	52.41	1.55	10.0 %	40.73	43.95	47.17	50.38	53.60	56.82	60.04
1.50	9.8 %	50.10	50.68	51.29	51.94	52.63	53.37	54.17	1.50	9.8 %	41.96	45.28	48.61	51.94	55.26	58.59	61.92
1.45	9.5 %	51.59	52.21	52.88	53.60	54.36	55.18	56.06	1.45	9.5 %	43.26	46.71	50.15	53.60	57.04	60.49	63.93
1.41	9.3 %	53.17	53.86	54.59	55.38	56.22	57.12	58.09	1.41	9.3 %	44.67	48.24	51.81	55.38	58.94	62.51	66.08
1.32	8.8 %	56.66	57.49	58.38	59.34	60.37	61.49	62.69	1.32	8.8 %	47.80	51.65	55.49	59.34	63.19	67.04	70.89

• Revenue is expected to grow based on the continuous expansion in the use of display technology.



Valuation							
	2016	2017	2018	2019	2020e	2021e	2022e
Price / Book	2.2 x	3.2 x	2.6 x	2.2 x	1.2 x	1.2 x	1.1 x
Book value per share ex intangibles	18.47	21.01	25.09	22.62	25.26	27.36	29.90
EV / Sales	0.7 x	1.1 x	0.9 x	1.0 x	0.5 x	0.5 x	0.4 x
EV / EBITDA	8.3 x	13.2 x	9.6 x	12.5 x	5.8 x	4.4 x	3.5 x
EV / EBIT	9.5 x	15.2 x	10.7 x	19.2 x	8.9 x	6.9 x	5.0 x
EV / EBIT adj.*	9.5 x	15.2 x	10.7 x	19.2 x	8.9 x	6.9 x	5.0 x
P / FCF	67.5 x	114.0 x	47.5 x	62.1 x	10.4 x	25.0 x	10.8 x
P/E	15.1 x	24.1 x	17.0 x	33.1 x	17.9 x	13.9 x	11.1 x
P / E adj.*	15.1 x	24.1 x	17.0 x	33.1 x	17.9 x	13.9 x	11.1 x
Dividend Yield	0.3 %	0.2 %	0.2 %	0.2 %	2.7 %	2.7 %	2.7 %
FCF Potential Yield (on market EV)	5.8 %	3.7 %	5.1 %	1.4 %	10.2 %	12.4 %	14.4 %
*Adjustments made for: -							





Consolidated profit and loss

In EUR m	2016	2017	2018	2019	2020e	2021e	2022e
Sales	197.1	218.3	241.4	203.3	185.0	215.0	225.9
Change Sales yoy	9.3 %	10.7 %	10.6 %	-15.8 %	-9.0 %	16.2 %	5.1 %
COGS	151.3	170.7	187.6	159.4	144.3	167.7	176.2
Gross profit	45.7	47.6	53.8	43.9	40.7	47.3	49.7
Gross margin	23.2 %	21.8 %	22.3 %	21.6 %	22.0 %	22.0 %	22.0 %
Research and development	5.9	5.4	5.4	4.9	3.7	5.2	5.0
Sales and marketing	24.8	26.3	27.6	28.8	25.9	27.9	27.1
Administration expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	17.1	18.3	23.4	15.6	17.0	21.9	25.4
Margin	8.7 %	8.4 %	9.7 %	7.7 %	9.2 %	10.2 %	11.3 %
Depreciation of fixed assets	1.2	1.5	1.7	1.2	1.5	3.2	3.4
EBITA	15.8	16.8	21.7	14.4	15.5	18.6	22.1
Amortisation of intangible assets	0.8	0.9	0.9	4.3	4.4	4.4	4.4
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	15.0	15.9	20.8	10.2	11.1	14.2	17.6
Margin	7.6 %	7.3 %	8.6 %	5.0 %	6.0 %	6.6 %	7.8 %
EBIT adj.	15.0	15.9	20.8	10.2	11.1	14.2	17.6
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest expenses	0.1	0.1	0.1	0.6	0.6	0.6	0.6
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	15.0	15.8	20.7	9.6	10.5	13.6	17.0
Margin	7.6 %	7.2 %	8.6 %	4.7 %	5.7 %	6.3 %	7.5 %
Total taxes	4.7	5.2	6.5	3.1	3.2	4.1	5.1
Net income from continuing operations	10.2	10.6	14.3	6.5	7.4	9.5	11.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	10.2	10.6	14.3	6.5	7.4	9.5	11.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	10.2	10.6	14.3	6.5	7.4	9.5	11.9
Margin	5.2 %	4.9 %	5.9 %	3.2 %	4.0 %	4.4 %	5.3 %
Number of shares, average	3.5	3.5	3.5	3.5	3.5	3.5	3.5
EPS	2.90	3.01	4.05	1.85	2.09	2.70	3.38
EPS adj.	2.90	3.01	4.05	1.85	2.09	2.70	3.38
*Adjustments made for:							

Guidance: n.a.

Financial Ratios							
	2016	2017	2018	2019	2020e	2021e	2022e
Total Operating Costs / Sales	15.6 %	14.5 %	13.7 %	16.6 %	16.0 %	15.4 %	14.2 %
Operating Leverage	2.1 x	0.5 x	2.9 x	3.2 x	-1.0 x	1.7 x	4.8 x
EBITDA / Interest expenses	193.9 x	152.7 x	320.1 x	26.5 x	28.8 x	37.0 x	43.1 x
Tax rate (EBT)	31.6 %	32.8 %	31.1 %	32.3 %	30.0 %	30.0 %	30.0 %
Dividend Payout Ratio	4.1 %	4.0 %	3.0 %	6.5 %	47.9 %	37.0 %	29.6 %
Sales per Employee	591,829	655,423	724,976	610,553	555,603	645,610	678,407







2017

2018

- Gross margin - Total Operating Costs / Sales - EBIT margin





COMMENT

2016

17.5 %

15.0 %

12.5 %

10.0 %

7.5 %

5.0 %

2.5 %

0.0 %

2019 2020e 2021e 2022e


Consolidated balance sheet




In EUR m	2016	2017	2018	2019	2020e	2021e	2022e
Assets							
Goodwill and other intangible assets	4.9	5.5	5.5	19.8	19.0	17.5	17.1
thereof other intangible assets	1.2	1.8	3.1	17.4	15.0	13.5	13.1
thereof Goodwill	2.4	2.4	2.4	2.4	2.4	2.4	2.4
Property, plant and equipment	11.6	13.0	15.8	19.4	19.9	19.6	20.3
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	16.5	18.5	21.3	39.2	38.9	37.2	37.4
Inventories	44.0	42.8	52.9	41.5	37.0	43.0	45.2
Accounts receivable	23.0	27.1	29.0	27.9	27.9	29.5	27.9
Liquid assets	17.2	20.2	25.0	26.4	38.7	40.4	49.1
Other short-term assets	2.3	2.3	6.0	12.5	12.5	12.5	12.5
Current assets	86.6	92.4	112.8	108.4	116.1	125.5	134.7
Total Assets	103.0	110.9	134.1	147.6	154.9	162.6	172.1
Liabilities and shareholders' equity							
Subscribed capital	10.6	10.6	10.6	10.6	10.6	10.6	10.6
Capital reserve	24.1	24.1	24.1	24.1	24.1	24.1	24.1
Retained earnings	36.4	46.5	58.6	64.0	71.0	77.1	85.6
Other equity components	-1.1	-1.7	0.8	0.9	2.3	2.2	2.2
Shareholders' equity	70.0	79.6	94.0	99.6	108.0	114.0	122.5
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	70.0	79.6	94.0	99.6	108.0	114.0	122.5
Provisions	5.7	4.9	3.8	18.6	19.1	19.6	20.1
thereof provisions for pensions and similar obligations	1.6	1.6	1.6	1.6	1.6	1.6	1.6
Financial liabilities (total)	3.0	4.2	4.2	4.2	4.2	4.2	4.2
thereof short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	14.2	13.7	13.7	9.2	7.6	8.8	9.3
Other liabilities	10.1	8.4	18.4	16.0	16.0	16.0	16.0
Liabilities	33.0	31.3	40.1	48.0	46.9	48.6	49.6
Total liabilities and shareholders' equity	103.0	110.9	134.1	147.6	154.9	162.6	172.1

Financial Ratios

	2016	2017	2018	2019	2020e	2021e	2022e
Efficiency of Capital Employment							
Operating Assets Turnover	3.1 x	3.2 x	2.9 x	2.6 x	2.4 x	2.6 x	2.7 x
Capital Employed Turnover	3.4 x	3.3 x	3.2 x	2.6 x	2.5 x	2.7 x	2.9 x
ROA	62.1 %	57.5 %	67.0 %	16.6 %	18.9 %	25.6 %	31.9 %
Return on Capital							
ROCE (NOPAT)	19.1 %	17.4 %	20.5 %	9.0 %	10.1 %	12.9 %	15.6 %
ROE	15.7 %	14.2 %	16.5 %	6.7 %	7.1 %	8.6 %	10.1 %
Adj. ROE	15.7 %	14.2 %	16.5 %	6.7 %	7.1 %	8.6 %	10.1 %
Balance sheet quality							
Net Debt	-12.6	-14.4	-19.2	-20.7	-32.9	-34.7	-43.3
Net Financial Debt	-14.2	-16.0	-20.8	-22.2	-34.5	-36.2	-44.9
Net Gearing	-18.0 %	-18.1 %	-20.4 %	-20.7 %	-30.5 %	-30.4 %	-35.3 %
Net Fin. Debt / EBITDA	n.a.						
Book Value / Share	19.9	22.6	26.7	28.2	30.6	32.3	34.7
Book value per share ex intangibles	18.5	21.0	25.1	22.6	25.3	27.4	29.9



Book Value per Share in EUR



COMMENT

Published 06.05.2020

6

Consolidated cash flow statement




In EUR m	2016	2017	2018	2019	2020e	2021e	2022e
Net income	10.2	10.6	14.3	6.5	7.4	9.5	11.9
Depreciation of fixed assets	1.2	1.5	1.7	1.2	1.5	3.2	3.4
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.8	0.9	0.9	4.3	4.4	4.4	4.4
Increase/decrease in long-term provisions	-0.9	0.0	0.0	0.0	0.0	0.0	0.0
Other non-cash income and expenses	3.1	0.3	0.0	0.0	0.5	0.5	0.5
Cash Flow before NWC change	14.5	13.4	16.8	12.0	13.8	17.7	20.3
Increase / decrease in inventory	-7.0	1.3	-10.1	11.4	4.5	-6.0	-2.2
Increase / decrease in accounts receivable	-5.2	-4.1	-1.8	1.1	0.0	-1.6	1.6
Increase / decrease in accounts payable	4.1	-0.5	0.0	-4.5	-1.6	1.2	0.5
Increase / decrease in other working capital positions	0.0	-3.4	5.9	-9.4	0.0	0.0	0.0
Increase / decrease in working capital (total)	-8.2	-6.7	-6.1	-1.5	2.9	-6.4	-0.1
Net cash provided by operating activities [1]	6.3	6.7	10.7	10.4	16.7	11.3	20.2
Investments in intangible assets	-1.5	-1.5	-1.8	-6.3	-2.0	-3.0	-4.0
Investments in property, plant and equipment	-2.8	-2.9	-4.0	-4.0	-2.0	-3.0	-4.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-4.0	-4.4	-5.6	-7.0	-4.0	-6.0	-8.0
Change in financial liabilities	-4.0	1.2	0.0	0.0	0.0	0.0	0.0
Dividends paid	-0.4	-0.4	-0.4	-0.4	-0.4	-3.5	-3.5
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	-1.6	0.0	0.0	0.0
Net cash provided by financing activities [3]	-4.4	0.7	-0.4	-2.0	-0.4	-3.5	-3.5
Change in liquid funds [1]+[2]+[3]	-2.1	3.0	4.7	1.5	12.3	1.8	8.6
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	17.2	20.2	25.0	26.4	38.7	40.4	49.1

Financial Ratios

Financial Ratios							
	2016	2017	2018	2019	2020e	2021e	2022e
Cash Flow							
FCF	2.3	2.2	5.1	3.5	12.7	5.3	12.2
Free Cash Flow / Sales	1.2 %	1.0 %	2.1 %	1.7 %	6.9 %	2.5 %	5.4 %
Free Cash Flow Potential	8.2	8.9	11.4	2.8	10.1	12.1	12.7
Free Cash Flow / Net Profit	22.4 %	21.2 %	35.8 %	53.5 %	172.2 %	55.5 %	102.0 %
Interest Received / Avg. Cash	0.1 %	0.1 %	0.1 %	0.0 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	1.8 %	3.3 %	1.7 %	14.1 %	14.1 %	14.1 %	14.1 %
Management of Funds							
Investment ratio	2.2 %	2.0 %	2.4 %	5.0 %	2.2 %	2.8 %	3.5 %
Maint. Capex / Sales	2.1 %	1.9 %	2.3 %	4.8 %	2.1 %	2.7 %	3.4 %
Capex / Dep	212.4 %	184.4 %	226.1 %	188.2 %	67.6 %	78.3 %	102.2 %
Avg. Working Capital / Sales	24.7 %	25.0 %	25.7 %	31.6 %	31.8 %	28.1 %	28.2 %
Trade Debtors / Trade Creditors	162.1 %	198.1 %	211.4 %	303.1 %	367.1 %	335.2 %	300.0 %
Inventory Turnover	3.4 x	4.0 x	3.5 x	3.8 x	3.9 x	3.9 x	3.9 x
Receivables collection period (days)	43	45	44	50	55	50	45
Payables payment period (days)	34	29	27	21	19	19	19
Cash conversion cycle (Days)	115	108	120	124	129	125	119

CAPEX and Cash Flow in EUR m

Source: Warburg Research



Free Cash Flow Generation

Working Capital



Published 06.05.2020



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.

3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.

4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in
 -2- the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.

MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.

- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.				
Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)		
Data Modul	3, 5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005498901.htm		



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	131	64
Hold	61	30
Sell	8	4
Rating suspended	6	3
Total	206	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	35	81
Hold	5	12
Sell	0	0
Rating suspended	3	7
Total	43	100

PRICE AND RATING HISTORY DATA MODUL AS OF 06.05.2020



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Jan Bauer Renewables Jonas Blum Telco, Construction **Christian Cohrs** Industrials & Transportation Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg **Financial Services** Mustafa Hidir Automobiles, Car Suppliers Ulrich Huwald Health Care, Pharma Philipp Kaiser Real Estate Thilo Kleibauer Retail Consumer Goods

INSTITUTIONAL EQUITY SALES

tkleibauer@warburg-research.com **ES** +49 40 3282-2660 mniemann@mmwarburg.com +49 40 3282-2664 kschilling@mmwarburg.com +49 69 5050-7411 lbogdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2669 aeschweiler@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com

+49 40 3282-2678

+49 40 309537-280

+49 40 309537-270

+49 40 309537-155

+49 40 309537-240

+49 40 309537-175

+49 40 309537-120

+49 40 309537-258

+49 40 309537-185

+49 40 309537-230

+49 40 309537-255

+49 40 309537-260

+49 40 309537-257

+49 40 3282-2634

+49 40 3282-2702

+49 40 3282-2700

MMWA GO

www.factset.com

+49 40 3282-2632

aschaper@mmwarburg.com

edust@mmwarburg.com

omerckel@mmwarburg.com

milgenstein@mmwarburg.com

mheider@warburg-research.com

jbauer@warburg-research.com

jblum@warburg-research.com

ccohrs@warburg-research.com

fellmann@warburg-research.com

mfuhrberg@warburg-research.com

jfrey@warburg-research.com

mhidir@warburg-research.com

uhuwald@warburg-research.com

pkaiser@warburg-research.com

hrueschmeier@warburg-research.com

mrode@mmwarburg.com

SALES TRADING

Marc Niemann

Klaus Schilling

Tim Beckmann

Lyubka Bogdanova

Jens Buchmüller

Scandinavia, Austria

Ireland, Poland, Australia

Alexander Eschweiler

Germany, Luxembourg

Matthias Fritsch

United Kingdom

Bloomberg

Andrea Schaper

Sales Assistance

FactSet

United Kingdom

Head of Equity Sales, Germany

Head of Equity Sales, Germany

Oliver Merckel Head of Sales Trading Elyaz Dust Sales Trading Michael Ilgenstein Sales Trading

MACRO RESEARCH

For access please contact:

 Carsten Klude
 +49 40 3282-2572

 Macro Research
 cklude@mmwarburg.com

 Our research can be found under:
 warburg Research

 Warburg Research
 research.mmwarburg.com/en/index.html



Tobias Hald

United Kingdom

Austria, Poland

Sophie Hauer Roadshow/Marketing

Juliane Niemann

Roadshow/Marketing

Marcel Magiera

Bastian Quast

Sales Trading

Sales Trading

Sales Trading

Jörg Treptow

Investment Strategy

Thomson Reuters

Kerstin Muthig

Sales Assistance

Capital IQ

Dr. Christian Jasperneite

11

Switzerland

Maximilian Martin

Christopher Seedorf

+49 40 309537-256 ekuls@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-125 pschmidt@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-265 sstippig@warburg-research.com +49 40 309537-248 ctatar@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290 rvanderhorst@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

> +49 40 3282-2695 thald@mmwarburg.com +49 69 5050-7413 mmartin@mmwarburg.com +49 69 5050-7414 cseedorf@mmwarburg.com

+49 69 5050-7417 shauer@mmwarburg.com +49 40 3282-2694 jniemann@mmwarburg.com

+49 40 3282-2662 mmagiera@mmwarburg.com +49 40 3282-2701 bquast@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

www.thomsonreuters.com www.capitaliq.com

+49 40 3282-2703 kmuthig@mmwarburg.com

